Why the study?
Does empagliflozin reduce the combined risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction?
Population
Patients with heart failure and a preserved ejection fraction, with or without diabetes
Key result
Empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients with preserved ejection fraction, regardless of diabetes status.
Authors
Loading...
Supports empagliflozin initiation in HFpEF irrespective of diabetes; extends SGLT2i benefits to preserved ejection fraction.
Does empagliflozin reduce the combined risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction?
Empagliflozin reduces the composite risk of cardiovascular death or heart failure hospitalization in patients with HFpEF, independent of diabetes status.
Anker et al. (2021) studied this question. Empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients with preserved ejection fraction, regardless of diabetes status.